

Acute Promyelocytic Leukemia

Low risk APL who have received ATO plus ATRA induction therapy and planning to receive consolidation therapy

HEMAPL0002
 PAn Open-label Phase I Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients With Acute Promyelocytic Leukemia
 PI: Coutre
 Sponsor: Syros Pharmaceuticals, Inc.

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy